Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details)

v3.24.0.1
Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Segment Information [Line Items]      
Revenue € 1,085,354 € 983,680 € 843,920
Cost of sales 745,461 663,879 578,515
Gross Profit 339,893 319,801 265,405
Other operating income 10,423 18,850 9,386
Selling and Marketing expenses 24,978 26,086 20,448
Research and Development expenses 35,672 34,387 29,616
General and Administrative expenses 88,946 85,747 62,502
Operating Profit 200,720 192,431 162,225
Depreciation and amortization 78,480 64,822 56,383
Total assets 2,071,577 1,659,698  
Total liabilities 938,931 663,788  
External Customers      
Segment Information [Line Items]      
Revenue 1,085,354 983,680 843,920
Adjustments, Eliminations and Unallocated Items      
Segment Information [Line Items]      
Revenue (168,790) (117,057) (70,113)
Cost of sales (140,196) (97,317) (63,393)
Gross Profit (28,594) (19,740) (6,720)
Other operating income (223) (148)  
Selling and Marketing expenses 60 11,369 9,516
Research and Development expenses 599 2,676 1,886
General and Administrative expenses 10,998 (2,500) (8,392)
Operating Profit (40,474) (31,433) (9,730)
Depreciation and amortization (661) (1,170) (1,760)
Total assets (82,822) 29,723  
Total liabilities (118,067) 104,069  
Adjustments, Eliminations and Unallocated Items | Inter-Segment      
Segment Information [Line Items]      
Revenue (168,790) (117,057) (70,113)
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Segment Information [Line Items]      
Revenue 881,337 801,237 695,172
Cost of sales 591,107 526,370 465,304
Gross Profit 290,230 274,867 229,868
Other operating income 10,630 18,985 9,386
Selling and Marketing expenses 20,970 12,287 7,736
Research and Development expenses 27,653 25,169 23,467
General and Administrative expenses 64,658 73,816 58,996
Operating Profit 187,579 182,580 149,055
Depreciation and amortization 75,320 62,401 54,487
Total assets 1,614,801 1,259,124  
Total liabilities 658,954 511,022  
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 879,288 799,652 694,038
Biopharmaceutical and Diagnostic Solutions | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 2,049 1,585 1,134
Engineering | Operating Segments      
Segment Information [Line Items]      
Revenue 372,807 299,500 218,861
Cost of sales 294,550 234,826 176,604
Gross Profit 78,257 64,674 42,257
Other operating income 16 13  
Selling and Marketing expenses 3,948 2,430 3,196
Research and Development expenses 7,420 6,542 4,263
General and Administrative expenses 13,290 14,431 11,898
Operating Profit 53,615 41,284 22,900
Depreciation and amortization 3,821 3,591 3,656
Total assets 539,598 370,851  
Total liabilities 398,044 256,835  
Engineering | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 206,066 184,028 149,882
Engineering | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 166,741 115,472 68,979
Total Segments | Operating Segments      
Segment Information [Line Items]      
Revenue 1,254,144 1,100,737 914,033
Cost of sales 885,657 761,196 641,908
Gross Profit 368,487 339,541 272,125
Other operating income 10,646 18,998 9,386
Selling and Marketing expenses 24,918 14,717 10,932
Research and Development expenses 35,073 31,711 27,730
General and Administrative expenses 77,948 88,247 70,894
Operating Profit 241,194 223,864 171,955
Depreciation and amortization 79,141 65,992 58,143
Total assets 2,154,399 1,629,975  
Total liabilities 1,056,998 767,857  
Total Segments | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 1,085,354 983,680 843,920
Total Segments | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue € 168,790 € 117,057 € 70,113